Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash from Financing Activities (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Cash from Financing Activities for 13 consecutive years, with $9.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 54.7% to $9.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $256.0 million through Dec 2025, down 65.18% year-over-year, with the annual reading at $256.0 million for FY2025, 65.18% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $9.0 million at Madrigal Pharmaceuticals, down from $236.6 million in the prior quarter.
  • The five-year high for Cash from Financing Activities was $573.7 million in Q1 2024, with the low at $1.7 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $115.0 million, with a median of $46.0 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities soared 58194.5% in 2021, then tumbled 98.7% in 2025.
  • Over 5 years, Cash from Financing Activities stood at $19.5 million in 2021, then surged by 1255.37% to $264.3 million in 2022, then surged by 81.55% to $479.9 million in 2023, then tumbled by 95.88% to $19.8 million in 2024, then tumbled by 54.7% to $9.0 million in 2025.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $9.0 million, $236.6 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.